FH缺陷型肾细胞癌的基因组图谱及免疫检查点抑制联合酪氨酸激酶抑制的应答
该回顾性多中心研究纳入中国15个中心的77例FH缺陷型肾细胞癌患者,分析分子特征及一线系统治疗结局。在67例可评估患者中,与贝伐珠单抗联合厄洛替尼相比,免疫检查点抑制剂联合酪氨酸激酶抑制剂与更优的总生存(HR 0.19,95%CI 0.04-0.90)和无进展生存(HR 0.22,95%CI 0.07-0.71)相关。
要点
- 77例FH缺陷型肾细胞癌中70例为胚系FH改变(HLRCC相关),7例为体细胞FH缺失。
- 复发性致病改变见于NF2(6/57,11%)、CDH1(6/57,11%)、PIK3CA(6/57,11%)和TP53(5/57,8.8%)。
- 与贝伐珠单抗联合厄洛替尼相比,ICI/TKI联合治疗与更优总生存(HR 0.19,95%CI 0.04-0.90)和无进展生存(HR 0.22,95%CI 0.07-0.71)相关。
核心结论
- 研究描述了中国FH缺陷型肾细胞癌患者的基因组特征,并观察到晚期患者对ICI/TKI联合治疗的良好应答。
- 作者指出需要进一步研究以探讨该联合策略在此罕见癌症中的疗效。
研究设计与样本
- 回顾性多中心分析,纳入中国15个中心的77例FH缺陷型肾细胞癌病例。
主要发现
- 77例中70例为胚系FH改变(遗传性平滑肌瘤病肾细胞癌综合征[HLRCC]相关肾细胞癌),7例为体细胞FH缺失。
- 复发性致病改变见于NF2(6/57,11%)、CDH1(6/57,11%)、PIK3CA(6/57,11%)和TP53(5/57,8.8%)。
- 67例可评估一线系统治疗应答,其中贝伐珠单抗联合厄洛替尼12例、TKI单药29例、ICI/TKI 26例。
- 与贝伐珠单抗联合厄洛替尼相比,ICI/TKI联合治疗与更优的系统治疗总生存相关(HR 0.19,95%CI 0.04-0.90)。
- 与贝伐珠单抗联合厄洛替尼相比,ICI/TKI联合治疗与更优的一线治疗无进展生存相关(HR 0.22,95%CI 0.07-0.71)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 主要局限性为回顾性研究设计。
- 作者指出需要进一步研究以探讨该联合策略在此罕见癌症中的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: FH-deficient renal cell carcinoma (RCC) is a rare and exceptionally aggressive RCC subtype. There is currently limited understanding of the molecular alterations, pathogenesis, survival outcomes, and systemic therapy efficacy for this cancer. OBJECTIVE: To perform a retrospective multicenter analysis of molecular profiling and clinical outcomes for patients with FH-deficient RCC, with an emphasis on treatment response to first-line immune checkpoint inhibitor plus tyrosine kinase inhibitor (ICI/TKI) versus bevacizumab plus erlotinib (Bev/Erlo) combination therapy in patients with advanced disease. DESIGN, SETTING, AND PARTICIPANTS: The study included 77 cases of FH-deficient RCC from 15 centers across China. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Clinical characteristics, molecular correlates, 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging, and treatment outcomes were analyzed. RESULTS AND LIMITATIONS: A total of 77 patients were identified, including 70 cases with a germline FH alteration (hereditary leiomyomatosis RCC syndrome [HLRCC]-associated RCC) and seven patients with somatic FH loss. Recurrent pathogenic alterations were found in NF2 (six/57, 11%), CDH1 (six/57, 11%), PIK3CA (six/57, 11%), and TP53 (five/57, 8.8%). Sixty-seven patients were evaluable for response to first-line systemic therapy with Bev/Erlo (n = 12), TKI monotherapy (n = 29), or ICI/TKI (n = 26). ICI/TKI combination therapy was associated with more favorable overall survival on systemic treatment (hazard ratio [HR] 0.19, 95% confidence interval [CI] 0.04-0.90) and progression-free survival on first-line therapy (HR 0.22, 95% CI 0.07-0.71) compared to Bev/Erlo combination therapy. The main limitation is the retrospective study design. CONCLUSIONS: We described the genomic characteristics of FH-deficient RCC in an Asian population and observed a favorable response to ICI/TKI combinational therapy among patients with advanced disease. PATIENT SUMMARY: This real-world study provides evidence supporting the antitumour activity of combining molecular targeted therapy plus immunotherapy for kidney cancer deficient in fumarate hydratase. Further studies are needed to investigate the efficacy of this combination strategy in this rare cancer.
引用
- Xu Y, Kong W, Cao M, et al. Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma. Eur Urol. 2022. PMID: 35715365. doi:10.1016/j.eururo.2022.05.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。